Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62012TN0493

    Case T-493/12: Action brought on 14 November 2012 — Sanofi v OHIM — GP Pharm (GEPRAL)

    IO C 26, 26.1.2013, p. 56–56 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    26.1.2013   

    EN

    Official Journal of the European Union

    C 26/56


    Action brought on 14 November 2012 — Sanofi v OHIM — GP Pharm (GEPRAL)

    (Case T-493/12)

    2013/C 26/113

    Language in which the application was lodged: English

    Parties

    Applicant: Sanofi (Paris, France) (represented by: C. Hertz-Eichenrode, lawyer)

    Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

    Other party to the proceedings before the Board of Appeal: GP Pharm, SA (Sant Quinti de Mediona, Spain)

    Form of order sought

    The applicant claims that the Court should:

    Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 5 September 2012 in case R 201/2012-2; and

    Order OHIM to pay the costs.

    Pleas in law and main arguments

    Applicant for a Community trade mark: The other party to the proceedings before the Board of Appeal

    Community trade mark concerned: The word mark ‘GEPRAL’, for goods in class 5 — International Registration No 1010832 designating the European Union

    Proprietor of the mark or sign cited in the opposition proceedings: The applicant

    Mark or sign cited in opposition: International registration No 418607, with effect in Austria of the word mark ‘DELPRAL’, for goods in class 5

    Decision of the Opposition Division: Allowed the opposition in its entirety

    Decision of the Board of Appeal: Upheld the appeal and allowed the International registration to proceed in its entirety

    Pleas in law: Infringement of Article 8(1)(b) of Council Regulation No 207/2009.


    Top